| Similar Articles |
|---|
 |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.   |
The Motley Fool
January 28, 2009
Brian Orelli |
Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter. |
The Motley Fool
July 19, 2010
Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
The Motley Fool
January 27, 2011
Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
October 21, 2009
Brian Orelli |
Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession. |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
The Motley Fool
July 27, 2011
Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
The Motley Fool
March 24, 2011
Brian Orelli |
It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors. |
The Motley Fool
July 22, 2009
Brian Orelli |
Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences. |
The Motley Fool
May 24, 2011
Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
The Motley Fool
April 22, 2009
Brian Orelli |
Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy. |
The Motley Fool
February 18, 2010
Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back. |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
July 21, 2006
Brian Lawler |
Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet. |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note. |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool
August 9, 2011
Brian Orelli |
Some Potential Good News in Biotech The FDA should approve Gilead's Btripla. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
July 21, 2010
Brian Orelli |
15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth. |
The Motley Fool
December 21, 2004
Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
September 20, 2011
Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool
April 3, 2008
Brian Lawler |
A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs. |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
The Motley Fool
November 9, 2009
Dave Mock |
A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts. |
The Motley Fool
April 19, 2006
John Bluis |
Gilead's Got Cash Up to the Gills The pharmaceutical cashes in on bird-flu fears. The company's strong performance means that investors have to pay a slight premium for its shares. |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
March 31, 2011
Brian Orelli |
Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious. |
The Motley Fool
June 19, 2009
Brian Orelli |
Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies. |
The Motley Fool
October 7, 2011
Brian Orelli |
A Little Help, Please Gilead pumps up the pipeline. |
The Motley Fool
June 25, 2010
Brian Orelli |
Diversification Times 50,000 Gilead Sciences diversifies any way it can. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
The Motley Fool
December 16, 2009
Brian Orelli |
Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising. |
The Motley Fool
June 28, 2011
Brian Orelli |
HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
BusinessWeek
September 2, 2010
Simeon Bennett |
David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS. |
The Motley Fool
January 25, 2008
Brian Lawler |
What's Not to Like About Gilead? Gilead is looking more and more like a diversified pharma with a robust clinical-stage pipeline and growing cash flows. |
The Motley Fool
June 12, 2008
Brian Lawler |
Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright. |
The Motley Fool
September 7, 2007
Brian Orelli |
Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
September 18, 2006
Gene G. Marcial |
Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
The Motley Fool
November 27, 2009
Brian Orelli |
A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence. |
The Motley Fool
May 28, 2009
Brian Orelli |
How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now? |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
